This page shows the latest darvadstrocel news and features for those working in and with pharma, biotech and healthcare.
Will treat perianal fistulas in adult patients with Crohn’s disease. Takeda has chalked up a big win this week after receiving a European licence for Alofisel (darvadstrocel), marking the first
Takeda’s bid comes shortly after TiGenix’ CX-601 (darvadstrocel), an allogeneic (donor) stem cell therapy for Crohn’s patients with perianal fistulas, was recommended for approval by the EU Committee
The Committee for Medicinal Products for Human Use (CHMP) backed the allogeneic (donor) stem cell therapy – Cx601 (darvadstrocel) – as a new therapeutic option for patients who do not respond to current
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel), an allogeneic stem cell therapy
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...